Please login to the form below

Not currently logged in
Email:
Password:

Ruvise

This page shows the latest Ruvise news and features for those working in and with pharma, biotech and healthcare.

Novartis withdraws application for Ruvise approval in EU

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension. The European Medicines Agency (EMA) has said that Novartis has withdrawn its marketing application for Ruvise in the treatment of high blood pressure. ... Ruvise (imatinib mesylate) is already

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics